Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
J Ethnopharmacol. 2011 Jan 27;133(2):803-9. doi: 10.1016/j.jep.2010.11.007. Epub 2010 Nov 9.
Cornus kousa F.Buerger ex Miquel, an oriental medicinal plant, has been traditionally used for the treatment of hyperglycemia, but its molecular mechanism remains unknown. The goal of this study was to investigate the peroxisome proliferator-activated receptor γ (PPARγ) ligand-binding activity of Cornus kousa and to determine the effects of Cornus kousa on insulin sensitization in 3T3-L1 cells for the treatment of type 2 diabetes.
PPARγ luciferase transactivation assay was used to evaluate the PPARγ ligand-binding activity of Cornus kousa leaf extract. Western blot analysis, oil Red O staining, and glucose uptake assay were performed to evaluate PPARγ agonistic activity and insulin sensitizing effects of Cornus kousa leaf extract (CKE) in 3T3-L1 cells.
CKE increased PPARγ ligand-binding activity in a dose-dependent manner. In addition, CKE enhanced adipogenesis and the expression of PPARγ target proteins, including glucose transporter 4 (GLUT4) and adiponectin, as well as proteins involved in adipogenesis, including PPARγ and CCAAT/enhancer binding protein α (C/EBPα) in 3T3-L1 adipocytes. Furthermore, CKE led to significant induction of glucose uptake and stimulated insulin signaling, but not to activation of AMP-activated protein kinase (AMPK) signaling. The enhanced glucose uptake by CKE were abolished by treatment with bisphenol a diglycidyl ether (BADGE), a PPARγ antagonist, or LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), but not by compound C, an AMPK inhibitor.
Consistent with the high PPARγ ligand-binding activity, CKE increased glucose uptake through PPARγ activation and insulin signaling. These results suggest that CKE could have pharmacological effects for the treatment of hyperglycemia and type 2 diabetes.
山茱萸(Cornus kousa F.Buerger ex Miquel)是一种东方药用植物,传统上用于治疗高血糖症,但它的分子机制尚不清楚。本研究的目的是研究山茱萸叶提取物对过氧化物酶体增殖物激活受体γ(PPARγ)配体结合活性的影响,并确定山茱萸叶提取物(CKE)对胰岛素敏化的作用,以治疗 2 型糖尿病。
采用 PPARγ 荧光素酶转激活测定法评价山茱萸叶提取物的 PPARγ 配体结合活性。采用 Western blot 分析、油红 O 染色和葡萄糖摄取测定法评价山茱萸叶提取物(CKE)在 3T3-L1 细胞中对 PPARγ 激动活性和胰岛素增敏作用的影响。
CKE 呈剂量依赖性增加 PPARγ 配体结合活性。此外,CKE 增强了 3T3-L1 脂肪细胞中的脂肪生成和 PPARγ 靶蛋白的表达,包括葡萄糖转运蛋白 4(GLUT4)和脂联素,以及脂肪生成相关蛋白,包括 PPARγ 和 CCAAT/增强子结合蛋白α(C/EBPα)。此外,CKE 导致葡萄糖摄取显著增加,并刺激胰岛素信号,但不激活 AMP 激活的蛋白激酶(AMPK)信号。用 PPARγ 拮抗剂双酚 A 二缩水甘油醚(BADGE)或磷酸肌醇 3-激酶(PI3K)抑制剂 LY294002 处理可消除 CKE 增强的葡萄糖摄取,但用 AMPK 抑制剂 Compound C 处理则不能消除。
与高 PPARγ 配体结合活性一致,CKE 通过 PPARγ 激活和胰岛素信号增加葡萄糖摄取。这些结果表明,CKE 可能具有治疗高血糖和 2 型糖尿病的药理作用。